文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

晚期MDS或AML患者异基因造血干细胞移植后接种自体原始粒细胞混合GM-K562细胞的疫苗

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.
PubMed 文献 · Blood Adv · 2017-11-14

该临床试验评估了MDS或AML患者异基因造血干细胞移植后接种自体原始粒细胞混合分泌粒细胞-巨噬细胞集落刺激因子的K562细胞疫苗。33例患者入组,疫苗毒性以注射部位反应最常见,1例发生严重嗜酸性粒细胞增多并死于嗜酸性心肌炎。中位随访67个月,5年无进展生存率和总生存率均为39%;移植时疾病活跃者与缓解者5年OS和PFS相似。

要点

  • 33例MDS或AML患者移植后接种自体原始粒细胞混合GM-K562疫苗,1例发生严重嗜酸性粒细胞增多并死于嗜酸性心肌炎。
  • 中位随访67个月,2-4级急性GVHD和慢性GVHD累积发生率分别为24%和33%,复发率48%,非复发死亡率9%。
  • 移植时疾病活跃者与移植时原始细胞<5%者5年OS和PFS相似;针对血管生成素-2的抗体反应与更优OS和PFS相关。

核心结论

  • GM-K562/白血病细胞疫苗接种可诱导生物学活性,即使在移植时疾病活跃的MDS/AML患者中也是如此。

研究设计与样本

  • 临床试验:MDS或AML且骨髓原始细胞≥5%的患者在异基因造血干细胞移植前采集原始粒细胞,移植后约第+30天开始接种6次由照射过的自体原始粒细胞与GM-K562混合制成的疫苗。
  • 共入组33例患者,其中AML 25例、MDS 8例;16例(48%)在移植时骨髓原始细胞≥5%。
  • 基于他克莫司的移植物抗宿主病预防直至疫苗完成(约第100天)才减量。

主要发现

  • 最常见的疫苗毒性为注射部位反应;1例患者发生严重嗜酸性粒细胞增多并死于嗜酸性心肌炎。
  • 中位随访67个月,2-4级急性GVHD和慢性GVHD的累积发生率分别为24%和33%;复发率和非复发死亡率分别为48%和9%。
  • 5年无进展生存率和总生存率均为39%。
  • 移植时疾病活跃(骨髓原始细胞≥5%)的接种患者与移植时骨髓原始细胞<5%的接种患者相比,5年OS相似(44% vs 35%,P = .81),5年PFS相似(44% vs 35%,P = .34)。
  • 接种后针对血管生成素-2的抗体反应与更优的OS相关(HR 0.43,P = .031),也与更优的PFS相关(HR 0.5,P = .036)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a clinical trial testing vaccination of autologous myeloblasts admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells after allogeneic hematopoietic stem cell transplantation (HSCT). Patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with ≥5% marrow blasts underwent myeloblast collection before HSCT. At approximately day +30, 6 vaccines composed of irradiated autologous myeloblasts mixed with GM-K562 were administered. Tacrolimus-based graft-versus-host disease (GVHD) prophylaxis was not tapered until vaccine completion (∼day 100). Thirty-three patients with AML (25) and MDS (8) enrolled, 16 (48%) had ≥5% marrow blasts at transplantation. The most common vaccine toxicity was injection site reactions. One patient developed severe eosinophilia and died of eosinophilic myocarditis. With a median follow-up of 67 months, cumulative incidence of grade 2-4 acute and chronic GVHD were 24% and 33%, respectively. Relapse and nonrelapse mortality were 48% and 9%, respectively. Progression-free survival (PFS) and overall survival (OS) at 5 years were 39% and 39%. Vaccinated patients who were transplanted with active disease (≥5% marrow blasts) had similar OS and PFS at 5 years compared with vaccinated patients transplanted with <5% marrow blasts (OS, 44% vs 35%, respectively, P = .81; PFS, 44% vs 35%, respectively, P = .34). Postvaccination antibody responses to angiopoietin-2 was associated with superior OS (hazard ratio [HR], 0.43; P = .031) and PFS (HR, 0.5; P = .036). Patients transplanted with active disease had more frequent angiopoeitin-2 antibody responses (62.5% vs 20%, P = .029) than those transplanted in remission. GM-K562/leukemia cell vaccination induces biologic activity, even in patients transplanted with active MDS/AML. This study is registered at www.clinicaltrials.gov as #NCT 00809250.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ho VT, Kim HT, Bavli N, et al. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017. PMID: 29296875. doi:10.1182/bloodadvances.2017009084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。